Search results for "hepatology"

showing 10 items of 2737 documents

Sex differences in the relationship among alcohol, smoking, and Helicobacter pylori infection in asymptomatic individuals

2020

Objective We aimed to investigate the relationship of Helicobacter pylori infection with alcohol and smoking. Methods We conducted a cross-sectional study among participants who underwent health check-ups for H. pylori infection between January 2013 and March 2017. We subsequently investigated the relationship of H. pylori infection with alcohol and smoking. Results A total of 7169 participants were enrolled in this study. The overall prevalence of H. pylori infection was 55.2%. Participants with H. pylori infection were more likely to be older than those without H. pylori infection. For male participants with H. pylori infection, multivariable logistic regression analysis indicated that bo…

medicine.medical_specialtyHelicobacter pylori infectionAlcoholLogistic regressionBiochemistryAsymptomatic03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineEpidemiologymedicinebiologybusiness.industryBiochemistry (medical)Cell BiologyGeneral MedicineOdds ratioHelicobacter pyloribiology.organism_classificationConfidence intervalchemistry030220 oncology & carcinogenesis030211 gastroenterology & hepatologymedicine.symptombusinessJournal of International Medical Research
researchProduct

Efficacy of 1-week ranitidine-bismuth-citrate (RBC)-based triple therapy for eradication of Helicobacter pylori infection

1999

medicine.medical_specialtyHelicobacter pylori infectionRanitidineGastroenterologyHelicobacter InfectionsRanitidineMetronidazoleInternal medicineOrganometallic CompoundsmedicineHumansPharmacology (medical)Clinical Trials as TopicHelicobacter pyloriHepatologybiologybusiness.industryAnti-ulcer AgentGastroenterologyHelicobacter pyloriAnti-Ulcer AgentsHelicobacter Infectionsbiology.organism_classificationAnti-Bacterial AgentsMetronidazoleRanitidine HydrochlorideDrug Therapy CombinationAntacidsbusinessmedicine.drugAlimentary Pharmacology & Therapeutics
researchProduct

Direct antiviral agents in hepatitis C virus related liver disease: Don’t count the chickens before they’re hatched

2021

Since molecules with direct-acting antiviral (DAA) became available, the landscape of the treatment of hepatitis C virus (HCV) infection has completely changed. The new drugs are extremely effective in eradicating infection, and treatment is very well tolerated with a duration of 8-12 wk. This review aims to report the outstanding clinical benefits of DAA and to highlight their critical disadvantages, identifying some clinically relevant hot topics. First, do the rates of virological response remain as high when patients with more advanced cirrhosis are considered? Large studies have shown slightly lower but still satisfactory rates of response in these patients. Nevertheless, modified sche…

medicine.medical_specialtyHepatitis B virusHepatitis C virusHepatitis C virus/hepatitis B virus coinfection.HepacivirusHypoglycemiamedicine.disease_causeGastroenterologyAntiviral Agents03 medical and health sciencesLiver diseasechemistry.chemical_compound0302 clinical medicineDiabetes mellitusInternal medicinemedicineAnimalsHumansAdvanced cirrhosisDirect antiviral activityHepatitis B virusbusiness.industryHepatitis C virusCoinfectionIncidence (epidemiology)RibavirinGastroenterologyvirus diseasesMinireviewsGeneral MedicineHepatitis C Chronicmedicine.diseaseHepatitis BHepatitis Cdigestive system diseaseschemistry030220 oncology & carcinogenesisCoinfection030211 gastroenterology & hepatologyNeoplasm Recurrence LocalLiver cancerbusinessLiver cancerChickensWorld Journal of Gastroenterology
researchProduct

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

2005

Background/Aims: Prediction of sustained virological response (SVR) during treatment would allow clinicians to identify patients most likely to benefit from therapy. Methods: Retrospective analysis of data from 1121 adults with chronic hepatitis C treated for 48 weeks with peginterferon alfa-2a (40 KD) 180 mu g/week plus placebo or ribavirin (1000/1200 mg/day), or interferon alfa-2b 3 MIU three times/week plus ribavirin in a randomized, multinational, study. Results: 67% of patients treated with peginterferon alfa-2a (40 KD)/ribavirin with early virological responses (HCV RNA negative or >= 2 log(10) decrease) at week 12 had SVRs at week 72 (HCV RNA 80 % of the planned ribavirin dose. Concl…

medicine.medical_specialtyHepatitis B virusviral hepatitisAlpha interferonPeginterferon-alfaInterferon alpha-2medicine.disease_causeGastroenterologyAntiviral AgentsPolyethylene Glycolschemistry.chemical_compoundpredictabilityInternal medicineRibavirinmedicinechronic hepatitis CHumansProbabilityRetrospective StudiesHepatitis B viruspeginterferon alfa-2a (40 KD)treatmentHepatologyDose-Response Relationship Drugbusiness.industryRibavirinvirus diseasesInterferon-alphaHepatitis CHepatitis C ChronicViral Loadmedicine.diseasedigestive system diseasesRecombinant ProteinsTreatment OutcomechemistryImmunologyRNA ViralDrug Therapy Combinationsustained virological responseViral hepatitisbusinessViral loadPeginterferon alfa-2amedicine.drugJournal of hepatology
researchProduct

Direct-acting antivirals for hepatitis C virus infections in patients co-infected with human immunodeficiency virus

2011

Summary Nearly three-quarters of human immunodeficiency virus–hepatitis C virus (HIV-HCV) coinfected patients in France currently need to be cured of their chronic HCV infection. The increase in sustained virological response rates obtained with the recently available HCV protease inhibitors in treatment-naive genotype-1 patients has generated considerable hope in these co-infected patients. However, several particularities (such as a higher baseline HCV load, more advanced liver fibrosis, frequent co-morbidities, and the risk of toxicity and drug–drug interactions) have not allowed the direct extrapolation of the results observed in HCV-monoinfected patients to patients with HIV-HCV co-inf…

medicine.medical_specialtyHepatitis C virusHuman immunodeficiency virus (HIV)HIV InfectionsContext (language use)medicine.disease_causeAntiviral AgentsViruschemistry.chemical_compoundPegylated interferonFibrosismedicineHumansIntensive care medicineHepatologybusiness.industryRibavirinGastroenterologyvirus diseasesHepatitis C Chronicmedicine.diseasechemistryImmunologyToxicitybusinessAlgorithmsmedicine.drugClinics and Research in Hepatology and Gastroenterology
researchProduct

Significant reductions in alcohol use after hepatitis C treatment: results from the ANRS CO13-HEPAVIH cohort

2017

BACKGROUND AND AIMS: Few data exist on changes to substance use patterns before and after hepatitis C virus (HCV) treatment. We used longitudinal data of HIV-HCV co-infected individuals to examine whether receiving pegylated interferon (Peg-IFN)-based therapy irrespective of HCV clearance could modify tobacco, cannabis and alcohol use. DESIGN: A prospective cohort of HIV-HCV co-infected individuals was enrolled from 2006. Participants' clinical data were retrieved from medical records and socio-demographic and behavioural characteristics were collected by yearly self-administered questionnaires. SETTING: Data were collected across 17 hospitals in France. PARTICIPANTS: All HIV-HCV co-infecte…

medicine.medical_specialtyHepatitis C virusMedicine (miscellaneous)Binge drinkingmedicine.disease_causeUnit of alcohol03 medical and health sciences0302 clinical medicinePegylated interferonInternal medicinemedicine030212 general & internal medicineProspective cohort studybiologybusiness.industryvirus diseasesHepatitis Cmedicine.diseasebiology.organism_classificationVirologydigestive system diseases3. Good healthPsychiatry and Mental healthCohort030211 gastroenterology & hepatologyCannabisbusinessmedicine.drugAddiction
researchProduct

Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C

2012

Summary.  Under-enrolment of women to randomized clinical trials, including chronic hepatitis C, has long been recognized. The aim of this study was to identify factors predictive of sustained virological response (SVR) to PEG IFN/Ribavirin antiviral therapy in relation to gender and reproductive status of female patients involved. Seven hundred and forty-six treatment-naive patients (431 men, 315 women) treated with Peg-IFNα-2a (180 μg/week) or Peg-IFNα-2b (1.5 μg/kg/week) plus ribavirin (800–1400  mg/day) for 24 or 48 weeks were studied between 2006 and 2010. Differences in SVR rate, overall and by gender were assessed after adjustment and propensity score matching. SVR was obtained in 44…

medicine.medical_specialtyHepatitis C virusPopulationmacromolecular substancesmedicine.disease_causeGastroenterologylaw.inventionchemistry.chemical_compoundRandomized controlled triallawVirologyInternal medicineMedicineeducationeducation.field_of_studyHepatologybusiness.industryRibavirintechnology industry and agriculturevirus diseasesmedicine.diseasedigestive system diseasesMenopauseInfectious DiseasesEndocrinologychemistryPropensity score matchingSteatosisMetabolic syndromebusinessJournal of Viral Hepatitis
researchProduct

Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation

2014

Background & Aims Recurrence of hepatitis C virus (HCV) infection after orthotopical liver transplantation (OLT) is common and associated with reduced graft and patient survival. The protease inhibitor telaprevir may enhance virological response rates in patients after OLT in combination with pegylated interferon-alfa and ribavirin. Pharmacokinetic studies have shown significant drug–drug interactions between telaprevir and immunosuppression (IS), but telaprevir pharmacokinetics in OLT patients with IS are unknown. Aim of the present study was to analyse telaprevir plasma concentrations in patients with HCV genotype 1 infection after OLT in comparison to patients without OLT and IS. Methods…

medicine.medical_specialtyHepatitis C virusmedicine.medical_treatmentPharmacologyLiver transplantationmedicine.disease_causeAntiviral AgentsGastroenterologyStatistics NonparametricTacrolimusPolyethylene GlycolsTelaprevirchemistry.chemical_compoundRecurrenceTandem Mass SpectrometryInternal medicineRibavirinmedicineHumansProspective StudiesImmunosuppression TherapyHepatologybusiness.industryRibavirinInterferon-alphaHepatitis Cmedicine.diseaseHepatitis CRecombinant ProteinsTacrolimusLiver TransplantationTransplantationsurgical procedures operativechemistryDrug Therapy CombinationDrug MonitoringbusinessViral hepatitisOligopeptidesChromatography Liquidmedicine.drugLiver International
researchProduct

Imaging features of histological subtypes of hepatocellular carcinoma: Implication for LI-RADS

2021

Background & Aims The histopathological subtypes of hepatocellular carcinoma (HCC) are associated with distinct clinical features and prognoses. This study aims to report Liver Imaging Reporting and Data System (LI-RADS)-defined imaging features of different HCC subtypes in a cohort of resected tumours and to assess the influence of HCC subtypes on computed tomography (CT)/magnetic resonance imaging (MRI) LI-RADS categorisation in the subgroup of high-risk patients. Methods This retrospective institutional review board-approved study included patients with resected HCCs and available histopathological classification. Three radiologists independently reviewed preoperative CT and MRI exams. T…

medicine.medical_specialtyHepatocellular carcinomaALT alanine transaminaseComputed tomographyRC799-869AST aspartate aminotransferaseOS overall survivalHistopathological subtypeMagnetic resonance imagingNOS-HCC not otherwise specified hepatocellular carcinomaInternal MedicinemedicineImmunology and AllergyIn patientComputed tomographyLI-RADS Liver Imaging Reporting and Data SystemLiver imagingHepatologymedicine.diagnostic_testbiologyUS ultrasoundbusiness.industryNot Otherwise SpecifiedGastroenterologyTIV tumour-in-veinMagnetic resonance imagingHBP hepatobiliary phaseDiseases of the digestive system. Gastroenterologymedicine.diseasedigestive system diseasesHistopathological subtypesCT computed tomographyRFS recurrence-free survivalAlanine transaminaseHepatocellular carcinomaSH-HCC steatohepatitic hepatocellular carcinomaCohortMTM-HCC macrotrabecular-massive hepatocellular carcinomabiology.proteinLI-RADSRadiologyAPHE arterial phase hyperenhancementbusinessHCC hepatocellular carcinomaMRI magnetic resonance imagingResearch ArticleJHEP Reports
researchProduct

The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C

2007

SUMMARY Aims  To assess whether host metabolic factors influence the degree of hepatic steatosis and fibrosis in patients infected with hepatitis C virus, and to evaluate the impact of anti-viral therapy on insulin resistance and serum levels of adipocytokines. Methods  Clinical and biochemical features, anthropometrical characteristics, and levels of fasting insulin, leptin, adiponectin and resistin were measured in ‘naive’ patients with chronic hepatitis C, before, during and after therapy with Peg-Interferon-alpha 2a plus Ribavirin. Results  Forty-eight patients were included (M/F 28/20; mean age 50.0 ± 12.6 years; 62.5% genotype-1). Body mass index was 26.4 ± 4.0 kg/m2, and visceral obe…

medicine.medical_specialtyHepatologyAdiponectinbusiness.industryLeptinInsulinmedicine.medical_treatmentGastroenterologyAdipokinemedicine.diseaseInsulin resistanceEndocrinologyFibrosisInternal medicinemedicinePharmacology (medical)ResistinSteatosisbusinessAlimentary Pharmacology & Therapeutics
researchProduct